Cwm, LLC Mirati Therapeutics, Inc. Transaction History

Cwm, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$41.99 - $62.38 $1,091 - $1,621	26 Added 2.22%	1,198 $70,000
Q3 2023 Oct 11, 2023	BUY	$27.8 - $45.35 $4,670 - $7,618	168 Added 16.73%	1,172 $51,000
Q2 2023 Aug 03, 2023	SELL	$36.13 - $49.49 $867 - $1,187	-24 Reduced 2.33%	1,004 $36,000
Q1 2023 Apr 28, 2023	SELL	$36.54 - $54.26 $1,717 - $2,550	-47 Reduced 4.37%	1,028 $38,000
Q4 2022 Feb 01, 2023	SELL	$41.27 - $98.62 $206 - $493	-5 Reduced 0.46%	1,075 $49,000

Q2 2022 Jul 28, 2022	BUY	$39.16 - $88.71 $38,533 - $87,290	984 Added 1025.0%	1,080 $73,000
Q1 2022 Apr 21, 2022	BUY	$75.82 - $150.97 $5,762 - $11,473	76 Added 380.0%	96 $8,000
Q4 2021 Jan 31, 2022	SELL	$132.01 - $190.29 $3,432 - $4,947	-26 Reduced 56.52%	20 $3,000
Q4 2019 Jan 27, 2020	SELL	$70.76 - $128.86 $35,663 - $64,945	-504 Reduced 91.64%	46 $6,000
Q1 2019 Apr 22, 2019	BUY	$43.65 - $78.95 $24,007 - $43,422	550 New	550 $40,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

Stay updated on Cwm, LLC with notifications on news.